Neuropsychiatric manifestations of systemic lupus erythematosus

Joint Bone Spine

Volumn 73, Issue 6, 2006, Pages 639-645

  Bruns, Alessandra ^a   Meyer, Olivier ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

Antiphospholipid antibodies; Antiribosomal antibodies; Central nervous system; Systemic lupus erythematosus

Indexed keywords

ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIGEN; AUTOANTIBODY; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOKINE; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUROLEPTIC AGENT; PHOSPHOLIPID ANTIBODY;

ACUTE CONFUSION; ANTIBODY PRODUCTION; ANXIETY DISORDER; ASEPTIC MENINGITIS; AUTONOMIC DYSFUNCTION; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROVASCULAR DISEASE; CLINICAL FEATURE; COGNITIVE DEFECT; CONFUSION; CRANIAL NEUROPATHY; CYTOKINE PRODUCTION; DEMENTIA; DEMYELINATING DISEASE; DISEASE SEVERITY; DRUG MEGADOSE; GUILLAIN BARRE SYNDROME; HEADACHE; HEMIANOPIA; HUMAN; INFECTION; INFLAMMATION; METABOLIC DISORDER; MONONEUROPATHY; MOOD DISORDER; MOTOR DYSFUNCTION; MYASTHENIA GRAVIS; NEUROPSYCHIATRY; PERSONALITY DISORDER; POLYNEUROPATHY; PREVALENCE; PSYCHOSIS; RIBOSOME; SEIZURE; SHORT SURVEY; SPINAL CORD DISEASE; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS; TREATMENT INDICATION; VASCULITIS; BRAIN VASCULITIS; MENTAL DISEASE; PATHOPHYSIOLOGY; REVIEW;

HUMANS; LUPUS VASCULITIS, CENTRAL NERVOUS SYSTEM; MENTAL DISORDERS; PREVALENCE;

EID: 33845489992     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2006.05.006     Document Type: Short Survey

References (90)

1. Van Dam A.P. Diagnosis and pathogenesis of CNS lupus. Rheumatol. Int. 11 (1991) 1-11
2. Carbotte R.M., Denburg S.D., and Denburg J.A. Prevalence of cognitive impairment in systemic lupus erythematosus. J. Nerv. Ment. Dis. 174 (1986) 357-364
3. West S.G. Neuropsychiatric lupus. Rheum. Dis. Clin. North Am. 20 (1994) 129-158
4. Hanly J.G. Evaluation of patients with CNS involvement in SLE. Baillieres Clin. Rheumatol. 12 (1998) 415-431
5. How A., Dent P.B., Liao S.K., and Denburg J.A. Antineuronal antibodies in neuropsychiatric systemic lupus erythematosus. Arthritis Rheum. 28 (1985) 789-795
6. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 42 (1999) 599-608
7. Denburg S.D., Carbotte R.M., and Denburg J.A. Psychological aspects of systemic lupus erythematosus: cognitive function, mood, and self-report. J. Rheumatol. 24 (1997) 998-1003
8. Jonsen A., Bengtsson A.A., Nived O., Ryberg B., and Sturfelt G. Outcome of neuropsychiatric systemic lupus erythematosus within a defined Swedish population: increased morbidity but low mortality. Rheumatol. 41 (2002) 1308-1312
9. Brey R.L., Holliday S.L., Saklad A.R., Navarrete M.G., Hermosillo-Romo D., Stallworth C.L., et al. Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. Neurology 58 (2002) 1214-1220
10. Ainiala H., Loukkola J., Peltola J., Korpela M., and Hietaharju A. The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology 57 (2001) 496-500
11. Hanly J.G., McCurdy G., Fougere L., Douglas J.A., and Thompson K. Neuropsychiatric events in systemic lupus erythematosus: attribution and clinical significance. J. Rheumatol. 31 (2004) 2156-2162
12. Ainiala H., Hietaharju A., Loukkola J., Peltola J., Korpela M., Metsanoja R., et al. Validity of the new American College of Rheumatology criteria for neuropsychiatric lupus syndromes: a population-based evaluation. Arthritis Rheum. 45 (2001) 419-423
13. Hanly J.G., and Liang M.H. Cognitive disorders in systemic lupus erythematosus. Epidemiologic and clinical issues. Ann. N. Y. Acad. Sci. 823 (1997) 60-68
14. Denburg S.D., and Denburg J.A. Cognitive dysfunction and antiphospholipid antibodies in systemic lupus erythematosus. Lupus 12 (2003) 883-890
15. Wekking E.M., Nossent J.C., van Dam A.P., and Swaak A.J. Cognitive and emotional disturbances in systemic lupus erythematosus. Psychother. Psychosom. 55 (1991) 126-131
16. Kozora E., Thompson L.L., West S.G., and Kotzin B.L. Analysis of cognitive and psychological deficits in systemic lupus erythematosus patients without overt central nervous system disease. Arthritis Rheum. 39 (1996) 2035-2045
17. Denburg S.D., Carbotte R.M., and Denburg J.A. Cognitive impairment in systemic lupus erythematosus: a neuropsychological study of individual and group deficits. J. Clin. Exp. Neuropsychol. 9 (1987) 323-339
18. Fisk J., Eastwood B., Sherwood G., and Hanly J.G. Patterns of cognitive impairment in patients with systemic lupus erythematosus. Br. J. Rheumatol. 33 Suppl (1993) S103
19. Miguel E.C., Pereira R.M., Pereira C.A., Baer L., Gomes R.E., de Sa L.C., et al. Psychiatric manifestations of systemic lupus erythematosus: clinical features, symptoms, and signs of central nervous system activity in 43 patients. Medicine 73 (1994) 224-232
20. Goodwin J.S., and Goodwin J.M. Cerebritis in lupus erythematosus. Ann. Intern. Med. 90 (1979) 437-438
21. Denburg J.A., Carbotte R.M., and Denburg S.D. Neuronal antibodies and cognitive function in systemic lupus erythematosus. Neurology 37 (1987) 464-467
22. Long A.A., Denburg S.D., Carbotte R.M., Singal D.P., and Denburg J.A. Serum lymphocytotoxic antibodies and neurocognitive function in systemic lupus erythematosus. Ann. Rheum. Dis. 49 (1990) 249-253
23. Denburg S.D., Carbotte R.M., Ginsberg J.S., and Denburg J.A. The relationship of antiphospholipid antibodies to cognitive function in patients with systemic lupus erythematosus. J. Int. Neuropsychol. Soc. 3 (1997) 377-386
24. Hanly J.G., Hong C., Smith S., and Fisk J.D. A prospective analysis of cognitive function and anticardiolipin antibodies in systemic lupus erythematosus. Arthritis Rheum. 42 (1999) 728-734
25. Menon S., Jameson-Shortall E., Newman S.P., Hall-Craggs M.R., Chinn R., and Isenberg D.A. A longitudinal study of anticardiolipin antibody levels and cognitive functioning in systemic lupus erythematosus. Arthritis Rheum. 42 (1999) 735-741
26. DeGiorgio L.A., Konstantinov K.N., Lee S.C., Hardin J.A., Volpe B.T., and Diamond B. A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat. Med. 7 (2001) 1189-1193
27. Kowal C., DeGiorgio L.A., Nakaoka T., Hetherington H., Huerta P.T., Diamond B., et al. Cognition and immunity; antibody impairs memory. Immunity 21 (2004) 179-188
28. Mitsikostas D.D., Sfikakis P.P., and Goadsby P.J. A meta-analysis for headache in systemic lupus erythematosus: the evidence and the myth. Brain 127 (2004) 1200-1209
29. Roldan C.A., Gelgand E.A., Qualls C.R., and Sibbitt Jr. W.L. Valvular heart disease as a cause of cerebrovascular disease in patients with systemic lupus erythematosus. Am. J. Cardiol. 95 (2005) 1441-1447
30. Sanna G., Bertolaccini M.L., Cuadrado M.J., Laing H., Khamashta M.A., Mathieu A., et al. Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J. Rheumatol. 30 (2003) 985-992
31. Mikdashi J., Krumholz A., and Handwerger B. Factors at diagnosis predict subsequent occurrence of seizures in systemic lupus erythematosus. Neurology 64 (2005) 2102-2107
32. LaRocca N.G. Psychosocial factors in multiple sclerosis and the role of stress. Ann. N. Y. Acad. Sci. 436 (1984) 435-442
33. Wekking E.M. Psychiatric symptoms in systemic lupus erythematosus: an update. Psychosom. Med. 55 (1993) 219-228
34. Creed F. Psychological disorders in rheumatoid arthritis: a growing consensus?. Ann. Rheum. Dis. 49 (1990) 808-812
35. Teh L.S., and Isenberg D.A. Antiribosomal P protein antibodies in systemic lupus erythematosus. A reappraisal. Arthritis Rheum. 37 (1994) 307-315
36. Bonfa E., Golombek S.J., Kaufman L.D., Skelly S., Weissbach H., Brot N., et al. Association between lupus psychosis and anti-ribosomal P protein antibodies. N. Engl. J. Med. 317 (1987) 265-271
37. Arnett F.C., Reveille J.D., Moutsopoulos H.M., Georgescu L., and Elkon K.B. Ribosomal P autoantibodies in systemic lupus erythematosus. Frequencies in different ethnic groups and clinical and immunogenetic associations. Arthritis Rheum. 39 (1996) 1833-1839
38. Gerli R., Caponi L., Tincani A., Scorza R., Sabbadini M.G., Danieli M.G., et al. Clinical and serological associations of ribosomal P autoantibodies in systemic lupus erythematosus: prospective evaluation in a large cohort of Italian patients. Rheumatol. 41 (2002) 1357-1366
39. Barile L., and Lavalle C. Transverse myelitis in systemic lupus erythematosus-the effect of IV pulse methylprednisolone and cyclophosphamide. J. Rheumatol. 19 (1992) 370-372
40. Kovacs B., Lafferty T.L., Brent L.H., and DeHoratius R.J. Transverse myelopathy in systemic lupus erythematosus: an analysis of 14 cases and review of the literature. Ann. Rheum. Dis. 59 (2000) 120-124
41. Cervera R., Asherson R.A., Font J., Tikly M., Pallares L., Chamorro A., et al. Chorea in the antiphospholipid syndrome. Clinical, radiologic, and immunologic characteristics of 50 patients from our clinics and the recent literature. Medicine 76 (1997) 203-212
42. Katzav A., Chapman J., and Shoenfeld Y. CNS dysfunction in the antiphospholipid syndrome. Lupus 12 (2003) 903-907
43. Ferreira S., Marques P., Carneiro E., D'Cruz D., and Gama G. Devic's syndrome in systemic lupus erythematosus and probable antiphospholipid syndrome. Rheumatology (Oxford) 44 (2005) 693-695
44. Lennon V.A., Wingerchuk D.M., Kryzer T.J., Pittock S.J., Lucchinetti C.F., Fujihara K., et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364 (2004) 2106-2112
45. Graham J.W., and Jan W. MRI and the brain in systemic lupus erythematosus. Lupus 12 (2003) 891-896
46. Harris E.N., Gharavi A.E., Mackworth-Young C.G., Patel B.M., Derue G., and Hughes G.R. Lupoid sclerosis: a possible pathogenetic role for antiphospholipid antibodies. Ann. Rheum. Dis. 44 (1985) 281-283
47. Marullo S., Clauvel J.P., Intrator L., Danon F., Brouet J.C., and Oksenhendler E. Lupoid sclerosis with antiphospholipid and antimyelin antibodies. J. Rheumatol. 20 (1993) 747-749
48. Ahmed F., Aziz T., and Kaufman L.D. Progressive multifocal leukoencephalopathy in a patient with systemic lupus erythematosus. J. Rheumatol. 26 (1999) 1609-1612
49. Arbusow V., Strupp M., Samtleben W., Hatz H., Bruckmann H., and Brandt T. Progressive multifocal leukoencephalopathy as a result of immunosuppressive therapy. Dtsch. Med. Wochenschr. 124 (1999) 653-656
50. Abialmouna J., Shoemaker D.W., Pullicino P.M., and Baer A.N. Marked cerebrospinal fluid pleocytosis in systemic lupus erythematosus related cerebral ischemia. J. Rheumatol. 19 (1992) 626-629
51. Codding C., Targoff I.N., and McCarty G.A. Aseptic meningitis in association with diclofenac treatment in a patient with systemic lupus erythematosus. Arthritis Rheum. 34 (1991) 1340-1341
52. Sekul E.A., Cupler E.J., and Dalakas M.C. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann. Intern. Med. 121 (1994) 259-262
53. McCune W.J., MacGuire A., Aisen A., and Gebarski S. Identification of brain lesions in neuropsychiatric systemic lupus erythematosus by magnetic resonance scanning. Arthritis Rheum. 31 (1988) 159-166
54. Vermess M., Bernstein R.M., Bydder G.M., Steiner R.E., Young I.R., and Hughes G.R. Nuclear magnetic resonance (NMR) imaging of the brain in systemic lupus erythematosus. J. Comput. Assist. Tomogr. 7 (1983) 461-467
55. Sibbitt Jr. W.L., Sibbitt R.R., Griffey R.H., Eckel C., and Bankhurst A.D. Magnetic resonance and computed tomographic imaging in the evaluation of acute neuropsychiatric disease in systemic lupus erythematosus. Ann. Rheum. Dis. 48 (1989) 1014-1022
56. Jacobs L., Kinkel P.R., Costello P.B., Alukal M.K., Kinkel W.R., and Green F.A. Central nervous system lupus erythematosus: the value of magnetic resonance imaging. J. Rheumatol. 15 (1988) 601-606
57. Bosma G.P., Rood M.J., Zwinderman A.H., Huizinga T.W., and van Buchem M.A. Evidence of central nervous system damage in patients with neuropsychiatric systemic lupus erythematosus, demonstrated by magnetization transfer imaging. Arthritis Rheum. 43 (2000) 48-54
58. Tourbah A., Deschamps R., Stievenart J.L., Lopez A., Iba-Zizen M.T., Lyon-Caen O., et al. Magnetic resonance imaging using FLAIR pulse sequence in white matter diseases. J. Neuroradiol. 23 (1996) 217-222
59. Gonzalez-Crespo M.R., Blanco F.J., Ramos A., Ciruelo E., Mateo I., Lopez Pino M.A., et al. Magnetic resonance imaging of the brain in systemic lupus erythematosus. Br. J. Rheumatol. 34 (1995) 1055-1060
60. Sanna G., Piga M., Terryberry J.W., Peltz M.T., Giagheddu S., Satta L., et al. Central nervous system involvement in systemic lupus erythematosus: cerebral imaging and serological profile in patients with and without overt neuropsychiatric manifestations. Lupus 9 (2000) 573-583
61. Bell C.L., Partington C., Robbins M., Graziano F., Turski P., and Kornguth S. Magnetic resonance imaging of central nervous system lesions in patients with lupus erythematosus. Correlation with clinical remission and antineurofilament and anticardiolipin antibody titers. Arthritis Rheum. 34 (1991) 432-441
62. Karassa F.B., Ioannidis J.P., Boki K.A., Touloumi G., Argyropoulou M.I., Strigaris K.A., et al. Predictors of clinical outcome and radiologic progression in patients with neuropsychiatric manifestations of systemic lupus erythematosus. Am. J. Med. 109 (2000) 628-634
63. Jarek M.J., West S.G., Baker M.R., and Rak K.M. Magnetic resonance imaging in systemic lupus erythematosus patients without a history of neuropsychiatric lupus erythematosus. Arthritis Rheum. 37 (1994) 1609-1613
64. Stimmler M.M., Coletti P.M., and Quismorio Jr. F.P. Magnetic resonance imaging of the brain in neuropsychiatric systemic lupus erythematosus. Semin. Arthritis Rheum. 22 (1993) 335-349
65. Cauli A., Montaldo C., Peltz M.T., Nurchis P., Sanna G., Garau P., et al. Abnormalities of magnetic resonance imaging of the central nervous system in patients with systemic lupus erythematosus correlate with disease severity. Clin. Rheumatol. 13 (1994) 615-618
66. Nossent J.C., Hovestadt A., Schonfeld D.H., and Swaak A.J. Single-photon-emission computed tomography of the brain in the evaluation of cerebral lupus. Arthritis Rheum. 34 (1991) 1397-1403
67. Oku K., Atsumi T., Furukawa S., Horita T., Sakai Y., Jodo S., et al. Cerebral imaging by magnetic resonance imaging and single photon emission computed tomography in systemic lupus erythematosus with central nervous system involvement. Rheumatol. 42 (2003) 773-777
68. Rubbert A., Marienhagen J., Pirner K., Manger B., Grebmeier J., Engelhardt A., et al. Single-photon-emission computed tomography analysis of cerebral blood flow in the evaluation of central nervous system involvement in patients with systemic lupus erythematosus. Arthritis Rheum. 36 (1993) 1253-1262
69. Rogers M.P., Waterhouse E., Nagel J.S., Roberts N.W., Stern S.H., Fraser P., et al. I-123 iofetamine SPECT scan in systemic lupus erythematosus patients with cognitive and other minor neuropsychiatric symptoms: a pilot study. Lupus 1 (1992) 215-219
70. Kovacs J.A., Urowitz M.B., Gladman D.D., and Zeman R. The use of single photon emission computerized tomography in neuropsychiatric SLE: a pilot study. J. Rheumatol. 22 (1995) 1247-1253
71. Waterloo K., Omdal R., Sjoholm H., Koldingsnes W., Jacobsen E.A., Sundsfjord J.A., et al. Neuropsychological dysfunction in systemic lupus erythematosus is not associated with changes in cerebral blood flow. J. Neurol. 248 (2001) 595-602
72. Sibbitt Jr. W.L., and Sibbitt R.R. Magnetic resonance spectroscopy and positron emission tomography scanning in neuropsychiatric systemic lupus erythematosus. Rheum. Dis. Clin. North Am. 19 (1993) 851-868
73. Meyer G.J., Schober O., Stoppe G., Wildhagen K., Seidel J.W., and Hundeshagen H. Cerebral involvement in systemic lupus erythematosus (SLE): comparison of positron emission tomography (PET) with other imaging methods. Psychiatry Res. 29 (1989) 367-368
74. Denburg S.D., Carbotte R.M., and Denburg J.A. Corticosteroids and neuropsychological functioning in patients with systemic lupus erythematosus. Arthritis Rheum. 37 (1994) 1311-1320
75. Trevisani V.F., Castro A.A., Neves Neto J.F., and Atallah A.N. Cyclophosphamide versus methylprednisolone for the treatment of neuropsychiatric involvement in systemic lupus erythematosus. Cochrane Database Syst. Rev. (2000) [CD002265]
76. Baca V., Lavalle C., Garcia R., Catalan T., Sauceda J.M., Sanchez G., et al. Favorable response to intravenous methylprednisolone and cyclophosphamide in children with severe neuropsychiatric lupus. J. Rheumatol. 26 (1999) 432-439
77. Leung F.K., and Fortin P.R. Intravenous cyclophosphamide and high dose corticosteroids improve MRI lesions in demyelinating syndrome in systemic lupus erythematosus. J. Rheumatol. 30 (2003) 1871-1873
78. Boumpas D.T., Yamada H., Patronas N.J., Scott D., Klippel J.H., and Balow J.E. Pulse cyclophosphamide for severe neuropsychiatric lupus. Q. J. Med. 81 (1991) 975-984
79. Neuwelt C.M., Lacks S., Kaye B.R., Ellman J.B., and Borenstein D.G. Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus. Am. J. Med. 98 (1995) 32-41
80. Ramos P.C., Mendez M.J., Ames P.R., Khamashta M.A., and Hughes G.R. Pulse cyclophosphamide in the treatment of neuropsychiatric systemic lupus erythematosus. Clin. Exp. Rheumatol. 14 (1996) 295-299
81. Mok C.C., Lau C.S., Chan E.Y., and Wong R.W. Acute transverse myelopathy in systemic lupus erythematosus: clinical presentation, treatment, and outcome. J. Rheumatol. 25 (1998) 467-473
82. Galindo-Rodriguez G., Avina-Zubieta J.A., Pizarro S., Diaz de Leon V., Saucedo N., Fuentes M., et al. Cyclophosphamide pulse therapy in optic neuritis due to systemic lupus erythematosus: an open trial. Am. J. Med. 106 (1999) 65-69
83. McCune W.J., Golbus J., Zeldes W., Bohlke P., Dunne R., and Fox D.A. Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus. N. Engl. J. Med. 318 (1988) 1423-1431
84. Mok C.C., Lau C.S., and Wong R.W. Treatment of lupus psychosis with oral cyclophosphamide followed by azathioprine maintenance: an open-label study. Am. J. Med. 115 (2003) 59-62
85. Gorman C., Leandro M., and Isenberg D. Does B cell depletion have a role to play in the treatment of systemic lupus erythematosus?. Lupus 13 (2004) 312-316
86. Saito K., Nawata M., Nakayamada S., Tokunaga M., Tsukada J., and Tanaka Y. Successful treatment with anti-CD20 monoclonal antibody (rituximab) of life-threatening refractory systemic lupus erythematosus with renal and central nervous system involvement. Lupus 12 (2003) 798-800
87. Sanna G., Bertolaccini M.L., and Mathieu A. Central nervous system lupus: a clinical approach to therapy. Lupus 12 (2003) 935-942
88. Gokhale Y.A., Bhide S., Rajadhyaksha S., Bichile L.S., and Hase N.K. Plasmapheresis: an adjunct therapy in severe progressive neuropsychiatric lupus. J. Assoc. Physicians India 49 (2001) 986-989
89. Crowther M.A., Ginsberg J.S., Julian J., Denburg J., Hirsh J., Douketis J., et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N. Engl. J. Med. 349 (2003) 1133-1138
90. Khamashta M.A., Cuadrado M.J., Mujic F., Taub N.A., Hunt B.J., and Hughes G.R. The management of thrombosis in the antiphospholipid-antibody syndrome. N. Engl. J. Med. 332 (1995) 993-997